246 related articles for article (PubMed ID: 6223590)
21. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: a multicentric controlled clinical trial. MPA-Hematology Italian Cooperative Group.
Chemioterapia; 1986 Apr; 5(2):134-9. PubMed ID: 2871945
[TBL] [Abstract][Full Text] [Related]
22. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
[TBL] [Abstract][Full Text] [Related]
23. Oral plus intramuscular medroxyprogesterone acetate (high dose Farlutal) in advanced breast cancer.
Ngelangel CA; Jimenez MV; Villalon AH; Agustin BM
Southeast Asian J Trop Med Public Health; 1985 Dec; 16(4):634-7. PubMed ID: 2940689
[TBL] [Abstract][Full Text] [Related]
24. [Plasma lipoprotein fractions in high-dose medroxyprogesterone acetate therapy in metastatic breast cancer].
Brockerhoff P; Grill HJ; Holzer A; Kreienberg R; Pollow K; Schicketanz KH; Schwarz V; Rathgen GH
Gynakol Rundsch; 1991; 31(4):189-200. PubMed ID: 1839014
[TBL] [Abstract][Full Text] [Related]
25. [A comparative study with 5'-DFUR alone or in combination with tamoxifen (TAM) or medroxyprogesterone acetate (MPA) for advanced or recurrent breast cancer].
Takatsuka Y; Yayoi E; Miyauchi K; Aikawa T; Maeura Y; Hirai T; Kotsuma Y
Gan To Kagaku Ryoho; 1992 May; 19(5):631-6. PubMed ID: 1533755
[TBL] [Abstract][Full Text] [Related]
26. [The medroxyprogesterone acetate serum level following various medroxyprogesterone acetate dose schedules in gynecologic oncology].
Husslein P; Egarter C; Eppel W; Salzer H; Spona J
Zentralbl Gynakol; 1988; 110(20):1277-82. PubMed ID: 2977043
[TBL] [Abstract][Full Text] [Related]
27. [High-dose gestagen therapy in breast cancer].
Beaufort F; Fereberger W
Wien Med Wochenschr; 1983 Apr; 133(7):169-73. PubMed ID: 6223450
[TBL] [Abstract][Full Text] [Related]
28. [Phase II study of NK 622 (toremifene citrate) in advanced breast cancer, a multicentral cooperative dose finding study].
Tominaga T; Abe O; Izuo M; Nomura Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):79-90. PubMed ID: 8422189
[TBL] [Abstract][Full Text] [Related]
29. Randomized trial of low- versus high-dose medroxyprogesterone acetate in the induction treatment of postmenopausal patients with advanced breast cancer.
Cavalli F; Goldhirsch A; Jungi F; Martz G; MermillodB ; Alberto P
J Clin Oncol; 1984 May; 2(5):414-9. PubMed ID: 6233398
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of CAF plus MPA with CAF plus TAM for advanced or recurrent breast cancer--Kyushu CAFT Study Group of Advanced or Recurrent Breast Cancer].
Mitsuyama S; Tashiro H; Koga T; Maehara Y; Ogawa M; Kakegawa T; Shimazu H; Sugimachi K; Tomita M; Nakamura Y
Gan To Kagaku Ryoho; 1995 Dec; 22(14):2073-80. PubMed ID: 8607618
[TBL] [Abstract][Full Text] [Related]
31. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
Sasagawa I; Satomi S; Umeda K; Katayama T
Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
[TBL] [Abstract][Full Text] [Related]
32. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
Stockdale AD; Chapman D; Mould GP; Rostom AY
Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
[TBL] [Abstract][Full Text] [Related]
33. [Clinical pharmacokinetics and practical consequences of optimal use of medroxyprogesterone acetate].
Etienne MC; Milano G; Namer M
Bull Cancer; 1993 May; 80(5):431-8. PubMed ID: 8173196
[TBL] [Abstract][Full Text] [Related]
34. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
35. [Effect of medroxyprogesterone acetate on the cell kinetics in primary breast cancer].
Doihara H; Takashima S; Saeki H; Takiyama W; Kurita A; Soga H; Tanada M; Yokoyama N; Moriwaki S
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2057-62. PubMed ID: 2145805
[TBL] [Abstract][Full Text] [Related]
36. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis.
Telimaa S; Puolakka J; Rönnberg L; Kauppila A
Gynecol Endocrinol; 1987 Mar; 1(1):13-23. PubMed ID: 2972167
[TBL] [Abstract][Full Text] [Related]
37. Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol.
Van Deijk WA; Blijham GH; Mellink WA; Meulenberg PM
Cancer Treat Rep; 1985 Jan; 69(1):85-90. PubMed ID: 3155651
[TBL] [Abstract][Full Text] [Related]
38. [A case of marked effectiveness using medroxyprogesterone acetate (MPA) in lung metastases of cancer of the uterine body].
Takeda M; Kubo K; Fukushima M; Hirayama J; Sekiguchi M
Gan To Kagaku Ryoho; 1990 Oct; 17(10):2113-7. PubMed ID: 2145808
[TBL] [Abstract][Full Text] [Related]
39. A phase II multi-institutional study of estra-1,3,5(10)-triene-3,17 beta-diol, 3-benzoate, 17[[4-[4-[bis(2-chloroethyl)amino]phenyl]-1- oxobutoxy]acetate] (KM2210), a novel antitumor agent, for advanced and recurrent breast carcinoma.
Kubota T; Abe O; Izuo M; Watanabe H; Enomoto K; Ohsawa N; Kuno K
Anticancer Res; 1993; 13(6B):2361-5. PubMed ID: 8135468
[TBL] [Abstract][Full Text] [Related]
40. [High-dosage medroxyprogesterone acetate treatment in advanced prostatic cancer].
Flamm J; Spona J
Wien Klin Wochenschr; 1987 Oct; 99(19):682-6. PubMed ID: 2961131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]